Category Covid-19

PIER MARIA FORNASARI
2021-03-05

An Israel study on in health-care workers at the Sheba Medical Centre vaccinated with BNT162b2 vaccine shows substantial early reductions in Covid-19 infections following firts dose administration

There has been some research that suggests the Pfizer/BioNTech vaccine provides some protection after one dose. Researchers at Israel’s largest hospital looked at what happened after 7,000 staff got vaccinated with the first dose of the Pfizer/BioNTech vaccine. By the second to fourth week after they got the first shot, rates of symptomatic infection were down by

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-05

Can it work a single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster in a wide vaccination strategy ?

Vaccines to prevent COVID-19 infection are crucial for an effective global pandemic response. In The Lancet, Merryn Voysey and colleagues report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa. A subsequent report of

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

Transmission, reinfection and vaccine efficacy update for major SARS-CoV-2 variants B.1.1.7 (UK), B.1.3.5.1 (South Africa) and P1 (Brazil).

The topics was discussed in a recent webinar that the Massachusetts Consortium on Pathogen Readiness (MassCPR) held to “demystify” the new viral variants. Each consists of several mutations. Will the variants fuel “a novel stage of contagion, COVID 2.0?” opened George Daley, MD, PhD, dean of Harvard Medical School. “What has been unsettling is how many times mutations

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 B.1.1.7 (UK) variant is more transmissible with a 43%-90% higher reproduction number and could induce cases resurgences.

A variant of SARS-CoV-2 that emerged in southeast England in November 2020 is more transmissible than pre-existing variants, a new modeling study of Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, published on Science, finds. Further analyses suggest the variant B.1.1.7 will lead to large resurgences of COVID-19 cases.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

EMA starts rolling review of the Sputnik V COVID-19 vaccine

EMA’s human medicines committee (CHMP) has started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine1 developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology. The EU applicant for this medicine is R-Pharm Germany GmbH. The CHMP’s decision to start the rolling review is based on results from laboratory studies and clinical studies in adults.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-03-04

SARS-CoV-2 variant B.1.1.7 (so called UK) is susceptible to neutralizing antibodies elicited by wild type Spike vaccines

All current vaccines for COVID-19 utilize ancestral wild type SARS-CoV-2 Spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple Spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 501Y.V1 or 20I), contains eight

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-02-28

Study of MIS-C vs. severe COVID in children suggests a continuum of illness, but flags key differences that could guide care

Study in JAMA reports interim findings from CDC-funded Overcoming COVID-19 Public Health Surveillance Registry; other studies ongoing Multisystem inflammatory syndrome in children (MIS-C) was first formally recognized in May 2020 as a post-infectious syndrome in children exposed to the SARS-CoV-2 coronavirus. In today’s JAMA, a study led by Boston Children’s Hospital refines the medical understanding of MIS-C and helps

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-02-28

NIH Fauci and BARDA Disbrow: Janssen COVID-19 Vaccine proved 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

“The Janssen COVID-19 vaccine is a very welcome addition to the arsenal of COVID-19 vaccines and other prevention strategies. When tested among 45,000 volunteers, the single-injection vaccine proved 77 percent effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85 percent effective in preventing severe/critical COVID-19 occurring at least 28 days

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-02-27

Carolina clinical trial tests effectiveness of mouthwash to kill oral SARS-CoV-2

Laboratory experiments have shown mouthwash can quickly kill coronaviruses, but there’s no evidence mouthwash can prevent the virus from infecting people. The Adams School of Dentistry is investigating how well mouthwash works to reduce the amount of SARS-CoV-2. Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-02-26

A paper published in NEJM shows that in Israel BNT162b2 mRNA Covid-19 Vaccine reduced cases by 94%

The Pfizer BioNTech coronavirus vaccine produces as good results in the “real world” as have been previously documented in randomised trials. A case control study, which has been peer reviewed and published in the New England Journal of Medicine, compared 596 618 people who were newly vaccinated in Israel and matched them to unvaccinated controls. Two doses

Read More

No Comments InCovid-19